Dermagnostix announces the launch of the TargetDisk product line, expanding its portfolio with innovative molecular research tools designed for dermatological studies. The TargetDisk line represents the company’s new research portfolio, developed to support researchers in exploring the molecular mechanisms of the skin.

This week, Vienna became the meeting point for pathologists from all over the world at the 37th European Congress of Pathology. For Dermagnostix, it was an inspiring opportunity to connect with experts, exchange ideas, and shine a spotlight on our passion: molecular diagnostics in dermatopathology.

Dermagnostix GmbH, specialized in the development of molecular diagnostic tests for dermatological issues, starts its distribution partnership with Axon Lab AG on 1 September 2025.

Our CEO had the honor of being the special guest on the JuDerm podcast. In episode 13, they discussed the importance of implementing molecular diagnosis in patients today and how certain methods can facilitate the work of dermatologists, thereby ensuring an accurate diagnosis, which is essential for determining the appropriate therapies for each patient and

Die Dermagnostix GmbH aus Freiburg, spezialisiert auf die Entwicklung molekulardiagnostischer Tests für dermatologische Fragestellungen, erweitert ihr Leistungsportfolio durch die Übernahme und Fortführung der Fluoreszenzdetektor Technologie der Dialunox GmbH i.L. aus Stockach zum 01.07.2025.

The Dermagnostix GmbH from Freiburg, specialized on the development of molecular diagnostic tests for dermatology, expands its portfolio by the acquisition and continuation of the fluorescence detector technology of Dialunox GmbH i.L. (Stockach) as of July 1st 2025.

Natalie Garzorz-Stark, CEO and co-founder of Dermagnostix, has been awarded the Innovation Award Dermatology by BVDD for the groundbreaking approach to revolutionizing dermatological diagnostics with automated molecular tests.

Muhterem Aras and Nadyne Saint-Cast recently visited Dermagnostix. Together with Dermagnostix’ managing directors Natalie Garzorz-Stark and Ludwig Gutzweiler they discussed the challenges and opportunities for healthcare start-ups, highlighting the role of political support for private investments.